Celsion and Hisun Expand Immuno-Oncology Therapy Partnership In China
Celsion plans to bring its first-line immune-oncology drug into clinical studies in China in 2018, with the help from its long-term local partner Zhejiang Hisun Pharmaceuticals. The partnership with Hisun serves multiple strategic purposes for lower costs and quicker approvals in the country where immunotherapeutics is becoming hot new category of cancer treatment.
You may also be interested in...
Zhejiang Hisun Pharmaceuticals is continuing to enrich its pipeline through in-licensing deals, most recently with Nascent, while seeking out-licensing opportunities for its growing pipeline of clinical-stage biologics. The company is also looking to expand into other emerging markets through international partnerships, an executive says.
Celsion, a US company specialized in oncology, is advancing its new China OPTIMA study with ThermoDox, a doxorubicin preparation for primary liver cancer. CEO Michael Tardugno sat down with PharmAsia News to talk about the ongoing clinical process and the Nasdaq-listed firm’s broader development and commercial plans, in which China plays a key role.
New policies including the allowance of contract manufacturing under a new marketing holder system are fast changing the nascent biologics sector in China, where the just 2% market penetration for such products is offering plenty of room for a new crop of startups including CANbridge to grow and thrive.